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Abstract: Fabry disease is a rare inherited lysosomal storage disorder caused by a partial or complete deficiency of -
galactosidase A (GLA), resulting in the storage of excess cellular glycosphingolipids. Enzyme replacement therapy is 
available for the treatment of Fabry disease, but it is a costly, intravenous treatment. Alternative therapeutic approaches, 
including small molecule chaperone therapy, are currently being explored. High throughput screening (HTS) technologies 
can be utilized to discover other small molecule compounds, including non-inhibitory chaperones, enzyme activators, 
molecules that reduce GLA substrate, and molecules that activate GLA gene promoters. This review outlines the current 
therapeutic approaches, emerging treatment strategies, and the process of drug discovery and development for Fabry dis-
ease. 
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BACKGROUND 
  Fabry disease (OMIM 301500) is a hereditary, X-linked 
lysosomal storage disorder first described by the dermatolo-
gists William Anderson and Johann Fabry in 1898 [1]. The 
incidence of the disease is estimated to be 1 in 40,000 to 
117,000 males worldwide [1, 2]. The disorder is caused by a 
deficiency of the lysosomal enzyme -galactosidase A 
(GLA), which results in the accumulation of the glycosphin-
golipid, globotriaosylceramide (Gb3), in different cells and 
organs, notably in endothelial cells and smooth muscle cells 
of blood vessels [1]. The onset of symptoms usually occurs 
in childhood. By middle age, life-threatening complications 
often develop in untreated patients. Manifestations of this 
disease are not only encountered in affected hemizygous 
males, but are also seen in heterozygous females [3, 4]. Pa-
tients with Fabry disease present clinically with chronic neu-
ronopathic pain, gastrointestinal disturbances, a specific skin 
finding called angiokeratoma, progressive renal impairment, 
cardiomyopathy, premature myocardial infarctions, and 
stroke. Both life expectancy and quality of life are severely 
compromised. 
  To date, 431 mutations have been reported for the GLA 
gene (Human Gene Mutation Database, www.hgmd.cf.ac. 
uk). Of these, more than 57% are missense mutations. Pa-
tients with missense mutations often have some residual en-
zyme activity, ranging from 2% to 25% [1]. Studies of the  
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residual GLA activity of mutant forms of the enzyme re-
vealed that many had kinetic properties similar to the wild-
type enzyme, but were significantly less stable [5-7]. These 
results suggest that the compromised enzyme activity in 
many Fabry patients is due to protein misfolding, and/or the 
inability to traffic the enzyme to the lysosomes. Most likely, 
the mutant protein is retained in the ER and degraded prema-
turely. Therefore, the discovery of small molecules that as-
sist mutant enzymes to fold correctly may rescue them from 
premature degradation and increase the amount of active 
enzyme in the lysosomes. 
CURRENT TREATMENTS FOR FABRY DISEASE 
Enzyme Replacement Therapy 
  Enzyme replacement therapy (ERT) supplies recombi-
nant GLA to cells and reverses several of the metabolic and 
pathologic abnormalities. ERT has been available for the 
treatment of Fabry disease since 2001 and is administered 
intravenously once every two weeks [8, 9]. The two recom-
binant GLA preparations available for ERT are agalsidase 
alfa (Replagal, Shire Human Genetic Therapies, Cambridge, 
MA, 0.2 mg/kg per infusion), and agalsidase beta (Fabra-
zyme, Genzyme Corporation, Cambridge, MA, 1 mg/kg per 
infusion). However, only Fabrazyme is approved by the 
FDA for use in the USA [10]. ERT has been shown to have a 
positive effect on kidney and heart manifestations at an early 
phase of the disease, lessening pain and improving quality of 
life [9]. However, the long-term clinical benefits of ERT for 
Fabry patients are still unclear, especially regarding its abil-
ity to prevent premature strokes [11, 12]. Some patients also 
develop immune responses to infused recombinant enzymes 
[11]. The short half-life of the enzyme and the need for re-
peated administration of large amounts of enzyme are other 
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of lifelong treatment becomes a burden to patients with 
Fabry disease. 
Alternative Therapies 
  While ERT is the standard treatment strategy, many 
symptoms of Fabry disease can be managed through suppor-
tive and palliative approaches. Daily prophylactic doses of 
neuropathic pain agents, such as phenytoin [14], carba-
mazepine [15], and gabapentin [16] are effective in decreas-
ing the frequency and severity of pain episodes in many pa-
tients. Some patients need more potent analgesics, such as 
opioids, for pain management. For gastrointestinal distur-
bances, pancrelipase, metoclopramide, H2 blockers, lopera-
mide, and hydrochloride can be beneficial [17]. Various laser 
treatments for angiokeratomas have been attempted, but have 
not been helpful [18]. Instead, pedunculated lesions may be 
treated with liquid nitrogen prior to laser therapy [19]. 
  Therapeutic management primarily focuses on the con-
trol of blood pressure, lipids, and proteinuria [20, 21]. ACE 
inhibitors and/or blockers should be used in patients with 
proteinuria [16]. Hypertension and hypercholesterolemia 
should be managed appropriately. Prophylaxis with antico-
agulants is important in patients who have had ischemic at-
tacks or stroke [22], and permanent cardiac pacing should be 
considered in high-risk patients [19]. Furthermore, patients 
need to be encouraged to maintain a healthy lifestyle. A 
change in eating habits, which includes frequent small meals, 
can be helpful [16]. While renal failure is the most frequent 
cause of death in classic Fabry disease, in patients with ad-
vanced renal disease, dialysis or transplantation can prolong 
life [23]. However, even with the engrafted kidneys, other 
organ system damage continues, particularly vascular disease 
affecting the heart and brain [24]. It is clear that even with 
ERT, other treatments and preventative measures are neces-
sary to manage Fabry disease. 
EMERGING TREATMENT STRATEGIES FOR 
FABRY DISEASE 
  Emerging treatment strategies for Fabry disease involve 
the development of small molecule compounds, which are 
widely used for the treatment of a variety of diseases. Such 
small molecules account for approximately 80-90% of mar-
keted drugs. Small molecule drugs are usually effective, 
have quick responses, and can be administered orally. In 
addition, they can cross the blood-brain barrier, do not cause 
autoimmune responses, and have lower manufacturing costs. 
Gene therapy has also been explored for the treatment of 
Fabry disease. The experimental results were limited as the 
viral vectors were used to achieve in vivo gene transfer in 
murine models [25]. Some emerging drug development 
strategies for small molecule therapy of Fabry disease are 
illustrated in Fig. (1) and outlined in more detail below.  
Substrate Reduction Therapy 
  GLA hydrolyzes the terminal alpha-galactosyl moieties 
from glycosphingolipids. A deficiency in GLA causes the 
accumulation of the glycosphingolipid, globotriaosylcera-
mide, in lysosomes. Substrate reduction therapy (SRT) cir-
cumvents enzyme replacement/modification by inhibiting 
synthesis of globotriaosylceramide. This approach involves 
the use of a glucosylceramide synthase inhibitor, which 
would slow the rate of Gb3 synthesis, and thus decrease 
lysosomal storage. Even if GLA activity is low or undetect-
able, SRT may convert a severe disease phenotype to a 
milder one. N-butyldeoxynojirimycin (NB-DNJ), an imino-
sugar analog, has been used as a glucosylceramide synthase 
inhibitor [26]. However, the inhibitory effect of NB-DNJ is 
not very specific for glucosylceramide synthase and side 
effects are observed, including gastrointestinal complaints 
[27, 28]. Since ERT for Fabry disease only shows modest 
efficacy, combinatorial therapy using ERT and SRT is being 
considered as a treatment strategy. 
Residual Enzyme Activation  
  It is known that enzyme activity can be stimulated by 
small molecule activators. Enzyme activators may increase 
the residual activity of mutant GLA in the lysosomes of pa-
tients with Fabry disease, thereby lessening lysosomal stor-
age of the substrate and alleviating symptoms. However, 
these activators may not be beneficial if their efficacy is not 
high enough or if the residual activity of mutant GLA is in-
adequate. From the drug discovery point of view, it is much 
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more difficult to identify enzyme activators than inhibitors in 
compound library screens. Therefore, assays need to be de-
veloped specifically for the identification of small molecule 
enzyme activators. 
GLA Promoter Activation 
  Specific small molecule promoter activators may in-
crease the amount of GLA in lysosomes by stimulating ex-
pression of the target protein. Here, a promoter activator 
binds the GLA promoter in the nuclei of cells and enhances 
GLA transcription, thereby increasing the synthesis of mu-
tant GLA protein. This results in an increased amount of 
GLA in the lysosomes, as the enhancement of mutant en-
zyme expression could proportionally increase protein traf-
ficking to the lysosome [29]. Therefore, in Fabry patients 
with significant residual GLA enzyme activity, a small 
molecule promoter activator may correct lysosomal storage 
by amplifying the amount of enzyme in lysosomes. In order 
to identify small molecule GLA promoter activators, a per-
manent cell line transformed with a cDNA plasmid contain-
ing the promoter region of the GLA gene linked with a re-
porter gene such as luciferase has to be established. Promoter 
activator lead compounds may be found by high throughput 
screening of this reporter gene cell line against the com-
pound library. Once lead compounds are identified, chemis-
try optimization and compound development can begin.  
Protein Homeostasis Regulation (Proteostasis)  
  Another treatment strategy involves altering the proteo-
stasis network in cells, which consists of many highly regu-
lated biological pathways that influence protein synthesis, 
folding, trafficking, disaggregation and degradation [30]. 
Small molecule proteostasis regulators may be utilized to 
increase the amount of folded protein in the endoplasmic 
reticulum by increasing the proteostasis network capacity. 
This is achieved through the enhancement of signaling path-
ways and/or the transcription and translation of components 
in the proteostasis network [31]. Such increases and de-
creases in the proteostasis network capacity can promote 
either protein folding or degradation, respectively. It has 
recently been reported that diltiazem and verapamil, known 
calcium
  channel blockers, partially restored mutant glu-
cocerebrosidase folding, trafficking, and enzyme function in 
patient fibroblasts [32]. Although therapeutic concentrations 
of these calcium channel blockers cannot be reached in hu-
mans, there is potential for small molecule development us-
ing this new target. In addition, the combination of proteo-
stasis regulators with small molecule chaperones may further 
increase the amount of folded protein trafficked to lysosomes 
and thus enhance the therapy, although this hypothesis needs 
to be tested. 
Chemical Chaperone Therapy 
  Chemical chaperone therapy (CCT) has recently emerged 
as a potential therapeutic alternative for Fabry disease. 
Chemical chaperones are small molecules that bind to mu-
tant enzyme proteins and assist in their correct folding, matu-
ration, and trafficking to their functional site, such as the 
lysosome. It has been reported that some enzyme inhibitors 
and receptor antagonists can serve as chaperones for mutant 
enzymes and receptors, as they bind to the target protein 
tightly [33, 34]. The effects of chemical chaperones have 
been explored for various lysosomal storage disorders, in-
cluding Gaucher disease [35-38], Pompe disease [39, 40], 
Tay-Sachs/Sandhoff disease [41], GM1-gangliosidosis [42], 
as well as for Fabry disease. Recent studies have shown that 
chemical chaperones can improve the efficacy of enzyme 
replacement therapy for Gaucher disease, Pompe disease, 
and Fabry disease [43, 44]. One GLA inhibitor, 1-
deoxygalactonojirimycin (DGJ, marketed as Amigal
TM by 
Amicus Therapeutics, Inc.) is currently being studied in a 
phase 3 clinical trial as a chaperone therapeutic agent for 
Fabry disease [45].  
  However, increasing mutant enzyme activities with an 
inhibitor may not be an ideal solution in vivo, as the chaper-
one action may be functionally compromised by the inhibi-
tion of enzyme activity. In theory, an enzyme activator or a 
pure enzyme binder with chaperone activity would be a bet-
ter choice as a candidate for drug development. If an enzyme 
activator is used as a therapy, both the chaperone and en-
zyme stimulatory actions of the activator would synergisti-
cally increase enzyme activity in the lysosomes. Currently, 
no such small molecule activators with chaperone activity 
are available. The proper assay development and compound 
library screens for identifying new lead compounds remain 
to be explored. Cell based chaperone assays using tagged 
GLA proteins may be a useful new method to identify poten-
tial chaperone compounds in library screens.  
THE PROCESS OF SMALL MOLECULE DRUG DIS-
COVERY 
Overview 
  The drug discovery process has evolved from disease 
model based screens with low throughput, to mecha-
nism/molecular target based screens with high throughput in 
the last two decades. The current small molecule drug dis-
covery process includes target identification and validation, 
early lead discovery and optimization, preclinical safety de-
velopment, and clinical trials, and requires an average of 10 
to 15 years (Fig. 2). Modern target based drug discovery 
started in the late 1980s, when advancements in molecular 
biology and the Human Genome Project led to a wealth of 
new drug targets. Recombinant proteins/enzymes and target 
proteins expressed in cell lines became available as useful 
tools for identifying small molecule activators and inhibitors 
in compound library screens. The demand for the high 
throughput screening of molecular targets led to the rapid 
development of new assay/detection technologies and drug 
screening robots in the 1990s. Synthetic chemical com-
pounds for compound collections also became commercially 
available at reasonable costs. A screen using 1-3 million 
compounds to identify lead compounds for a single drug 
target has become a routine operation in the pharmaceutical 
industry over the last 10 years. 
  Compound screening methods and throughput have sig-
nificantly improved in the last 20 years. The initial test tube 
(1-5 ml) based screens have evolved to 96-well plates (100-
300 μl), and recently to high density 384-well (20-40 μl) and 
1536-well (2-8 μl) plates. The increase in well density has 
greatly enhanced compound screening throughput, and has 
also reduced screening costs. Primary screens traditionally 
use a single compound concentration due to the large size of 
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high throughput screening (qHTS) method has been devel-
oped , where compounds are screened at a 1:5 titration, and 
concentration-response curves are obtained for active com-
pounds immediately after the primary screen [46]. A primary 
screen with multiple compound concentrations increases the 
data quality, reduces the number of compounds being se-
lected for confirmation, and is particularly helpful for identi-
fying biphasic compounds that might be missed in a single 
concentration screen. However, the qHTS method may not 
be applicable in all screen scenarios as increasing reagent 
costs may prevent multiple concentration screens. Reduction 
in the library size to 200,000- 400,000 compounds, use of an 
alternative assay, or further assay miniaturization could bring 
down reagent costs and make multiple concentration screens 
more practical. 
  Once active compounds (“hits”) are identified from the 
primary screen, they must be tested further in secondary and 
tertiary assays to confirm their activity and selectivity. The 
compounds with the most drug-like chemical structures then 
undergo chemical optimization to improve potency, selectiv-
ity and reduce potential toxicity. Hundreds to thousands of 
newly synthesized analog compounds are rescreened to de-
termine structure-activity-relationships (SAR) as well as 
pharmacokinetic properties, such as drug absorption, distri-
bution, metabolism, and excretion properties. The com-
pounds with the highest potencies, selectivities, and most 
promising pharmacokinetic properties then move on to pre-
clinical development, where safety and efficacy in animal 
models is tested, before entering clinical trials. It is clear that 
target selection, assay development, and lead discovery play 
key roles in the drug discovery and development process. 
Identification of high quality, drug-like lead compounds is 
vital for success in the later stages of drug development. 
Assay Development 
  Primary screening assays should have the least possible 
assay steps (usually 3-6 steps), have a short incubation time 
(from a few minutes to a maximum of 3 days), be homoge-
nous (no wash step), have high repeatability, have physio-
logical relevance, and reagents should have a reasonable 
cost. For lysosomal hydrolases, including GLA, fluorescence 
assays are commonly used. Fluorogenic substrates, such as 
4-methylumbelliferyl--D-galactopyranoside (4MU--Gala) 
[47, 48] or resorufinyl -D-galactopyranoside (res--Gala) 
[49], can be used to measure GLA activity. Chromogenic 
substrates, such as p-nitrophenol--D-galactopyranoside [50, 
51] or naphthyl--D-galactopyranoside [52], are also avail-
able. However, absorbance assays are usually less sensitive 
than fluorescence assays, and cannot be easily miniaturized 
into a 1536-well plate format. 
  During assay development, various conditions, such as 
the buffer components, pH, incubation time and temperature, 
enzyme and substrate concentrations, and DMSO tolerance 
have to be evaluated and optimized prior to HTS. Since GLA 
is a lysosomal enzyme, an acidic buffer should be used. The 
incubation time should give sufficient fluorescence signal 
while being in the linear portion of the time course curve. To 
increase assay sensitivity, the minimum amount of enzyme 
which produces sufficient signal should be used, and the 
substrate concentration should be around or below the Km 
value. The effect of DMSO on enzyme activity is also im-
portant because it is commonly used as a solvent to dissolve 
compounds. Usually the concentration of DMSO in the assay 
should be less than 1%. 
Assay Validation 
  Known inhibitors or activators are commonly used to 
validate assay sensitivity, and to compare the assay in differ-
ent plate formats, such as in 96-, 384- and 1536-well plate 
formats. Potencies (IC50 or EC50 values) of the control com-
pounds should usually be within two fold of the reported 
value. A DMSO plate (no compounds) is used to determine 
the signal-to-basal (S/B) ratio, CV, and the Z’ factor of the 
assay. The S/B ratio (assay window) should be greater than 
2, and the CV should be smaller than 10%, but no greater 
than 20%. The Z’ factor is a parameter used to judge the 
quality of a screening assay, with a value greater than 0.5 
being acceptable for HTS. It is calculated using the follow-
ing equation: Z’ = 1 – (3*s.d.(1) + 3*s.d.(2))/(A-B), where 
s.d.(1) is the standard deviation of enzyme activity, s.d.(2) is 
the standard deviation of basal activity (without enzyme), A 
is the mean of enzyme activity and B is the mean of basal 
activity. Reagent stability over a 24 hour time period (en-
zyme and substrate) must be examined to ensure that the 
signal-to-basal ratio remains nearly constant throughout the 
continuous robotic screen. Usually, an enzyme assay with an 
S/B ratio greater than 3, CV less than 10% and Z’ factor 
greater than 0.5 is considered a robust screening assay. An 
S/B ratio of at least 2 is usually necessary for HTS.  
  After the DMSO plate test, a test screen with a smaller 
compound library is carried out to validate the screen per-
formance of the optimized assay. The LOPAC collection 
(Library of Pharmacologically Active Compounds, Sigma-
Aldrich), which consists of 1,280 compounds, is commonly 
used for this screening test [46]. The S/B ratio, Z’ and the hit 
rate of the primary screen can be assessed by this test screen. 
Since the LOPAC collection contains compounds that inter-
act with a broad range of targets, the hit rate obtained is usu-
ally higher than that obtained from the high throughput 
screen, which uses a much larger compound collection. 
However, this test screen is helpful in predicting the outcome 
of the large-scale compound screen. 
Large-Scale Compound Screen (HTS) 
  Once the assay is validated using a DMSO plate and the 
LOPAC library, and the results indicate that the assay is of 
sufficient quality (S/B ratio greater than 2 and Z’ factor 
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greater than 0.5), a full library screen using a robot is ready 
to be performed. HTS consumes a significant quantity of 
reagents, as several hundred to a few thousand plates are 
screened, depending on the size of the compound libraries 
and the assay conditions. The robotic screen is usually run 
continuously, which requires the reagents to be stable at 
room temperature or 4°C for at least 24 hours. Depending on 
the size of the compound collection, the screening can take 
anywhere from a few days to two weeks. 
  After the primary screen is complete, the data is loaded 
into a database for analysis. Traditionally, the percent inhibi-
tion or activation is used to calculate the hit rate at the com-
pound concentration selected for the screen. The expected hit 
rate is usually 0.1-1% of the compound collection. However, 
selection of active compounds from qHTS is based on the 
potencies (EC50/IC50) and the quality of the concentration 
response curves. In addition, structure clustering and early 
SAR analysis can be performed immediately on the primary 
screen results, which reduces the selection or “cherry-
picking” of too many compounds for hit confirmation.  
Confirmation and Secondary Screens 
  The hits from the primary screen are confirmed by testing 
them in the same assay. Once confirmed as hits, the com-
pounds are then tested for specificity. In the case of GLA, 
other lysosomal hydrolases can be used to assess compound 
selectivity, such as glucocerebrosidase, -glucosidase, and 
-N-acetylglucosaminidase. Like the GLA assay, these coun-
terscreen assays are fluorogenic and can be performed in a 
similar assay format. Because the same fluorophore is used 
in these counterscreen assays, false positive compounds, 
including fluorescence quenchers and fluorescent com-
pounds, can be eliminated. The ideal lead compound should 
have at least ten times less activity in the counterscreen as-
says.  
  The mode of inhibition of the lead inhibitors should be 
characterized in an enzyme kinetic assay. A series of 5-6 
substrate concentration response curves in the absence and 
presence of several concentrations of inhibitors are generated 
kinetically. A Lineweaver–Burk plot (double reciprocal plot) 
is commonly used to determine if the inhibition is competi-
tive, noncompetitive, or uncompetitive. Ki values can be 
obtained by using a computer program such as Prism
® 
(Graphpad, San Diego, CA). A rapid Ki assessment method 
has been developed, permitting measurement of the Ki val-
ues of 6 compounds in one 1536-well plate using a fluoro-
genic enzyme assay [38]. 
  Additional assays are needed to further characterize the 
lead compounds. In the case of GLA, the compound’s poten-
tial to be a chemical chaperone should be evaluated. This 
usually can be done either by determining if the lead com-
pounds are able to increase enzyme activity in whole cells or 
by visualizing decreased substrate storage or increased GLA 
protein in lysosomes.  
Whole Cell Enzyme Activity Assay 
  A whole cell enzyme activity assay can be used to test for 
potential GLA chaperoning. This involves the use of patient 
derived primary skin fibroblasts or lymphoblasts to measure 
the effect of the compounds on enzymatic activity. Briefly, 
the cells are cultured with or without the compounds in stan-
dard cell culture conditions for 2-5 days, and then GLA ac-
tivity is measured in whole cells using a fluorogenic sub-
strate, either 4MU--Gala or res--Gala. The substrates 
enter the cells via permeablization of cell membranes by 0.2 
M sodium acetate-PBS buffer (1:1 ratio) at pH 4.0 [38]. 
Compounds capable of enhancing GLA activity in patient 
cells would be considered potential chemical chaperones. 
Immunofluorescence Staining Assay 
  This assay involves the double immunofluorescence 
staining of Gb3 and the lysosomal membrane protein 1 
(LAMP1) after 2-5 days compound treatment [53]. Com-
pounds with chaperone activity would reduce Gb3 storage in 
the lysosome, and thus, Gb3 staining in cells should become 
distinctively diminished after treatment with active com-
pounds. Also, an anti-GLA antibody can be used to deter-
mine whether the compounds acted as chaperones, as re-
flected by the degree of co-localization with LAMP1 [54]. 
Lysotracker (Invitrogen), a fluorescent dye staining to the 
acidic compartments in cells, can be used to visualize the 
enlarged lysosomes. Chaperone compounds would increase 
the amount of GLA in lysosomes, thereby increasing cleav-
age of the substrate. As a result, smaller lysosomes would be 
observed though the false positive compounds which alter 
the intracellular pH should be eliminated.  
Natural Substrate Assay 
  The natural substrate for GLA, globotriaosylceramide 
(Gb3), is used to assess the compounds in a more physio-
logically relevant environment. Several methods have been 
reported to measure Gb3, including gas chromatogra-
phy/chemical ionization mass spectrometry (GC/CI-MS) 
after permethylation of glycolipids [55], HPLC with UV 
detection after perbenzoylation [56], and enzyme-linked im-
munosorbent assay [57]. Recently, a more sensitive and ro-
bust method has been developed which uses electrospray 
ionization mass spectrometry (ESI-MS) [58]. However, this 
method still has a relatively low throughput, and would only 
be useful for confirming the activity of a small number of 
compounds. 
GLA Western Blot  
  Western Blot analyses of patient-derived cells can be 
compared with normal cells to evaluate GLA protein matura-
tion after treatment with compounds. GLA is present in two 
main forms within cells, the immature ER form (51 kDa) and 
the mature lysosomal form (46 kDa) [53, 59, 60]. The inten-
sity of each band on the Western Blot, and the relative ratio 
of the two bands, provides information about protein expres-
sion and processing. 
Probe Identification and Optimization 
  Depending on the potency and selectivity of active com-
pounds identified in the above processes, a probe can be de-
fined if the potencies (IC50/EC50) of the identified agents are 
less than 1 μM, and if they selectively act on GLA and effec-
tively reduce Gb3 accumulation in patient cells. If the activ-
ity of the compounds is weak and/or the specificity poor, 
probe optimization can be carried out by chemists. The 
bioavailability of the active compound(s) is also optimized 
during this process. Fabry Disease – Current Treatment and New Drug Development  Current Chemical Genomics, 2010, Volume 4    55 
Further Testing in Animal Models 
  Several mouse models have been reported for Fabry dis-
ease. A complete GLA knockout model was generated that 
shows some Gb3 accumulation in various organs and tissues 
[61]. This model has been used for experiments with ERT, 
SRT, and gene therapy. However, this model is not useful 
for examining the effect of chemical chaperones because it 
has no mutant enzyme that can be enhanced by chaperones. 
However, a GLA knock-in mouse that contains the human 
mutation R301Q has been generated that may prove useful in 
answering this question [62]. Because the expression level of 
the human transgene is substantially higher than that of the 
endogenous gene, this mouse has no signs or symptoms of 
Fabry disease. However, it has been shown that the activity 
of the mutant GLA can be enhanced by DGJ in vivo [62]. 
Mouse models with mutations that still retain some enzyme 
activity will prove useful for testing probes identified from 
HTS.  
CONCLUSIONS 
  In summary, this review provides an overview of the 
current and emerging therapies for Fabry disease, and de-
scribes drug development strategies and methods. Although 
enzyme replacement therapy is effective, there is a need for 
other therapeutic strategies, which can either serve as pri-
mary or supplemental treatments. Small molecule drug dis-
covery is promising, as it could lead to new treatments for 
Fabry disease. The discovery of non-inhibitory chaperones, 
activators, or inhibitors of the enzymes that degrade gly-
cosphingolipids, would be a major breakthrough. The con-
tinued expansion of our knowledge regarding the biology 
and pathophysiology of Fabry disease, combined with rapid 
advances in drug discovery technologies, bring us closer to 
the discovery of new treatments for Fabry disease and give 
hope to people suffering from this complex and life-
threatening disease.  
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